Ornskov OK With Cinryze 'Cannibalization' As Shire Buys Dyax (And Keeps Baxalta Guessing)
This article was originally published in Scrip
Executive Summary
Shire PLC is to acquire Dyax Corp. for $37.30 in cash per Dyax share, valuing the US biotech at around $5.9bn upfront. Dyax's promising hereditary angioedema (HAE) treatment DX-2930 could generate annual global sales "of up to $2.0bn" if approved for the prevention of type 1 and type 2 HAE, according to Shire. It is likely some of this revenue would come from "cannibalizing" Shire's current successful HAE treatment Cinryze (C1 esterase inhibitor [human]), but this doesn't concern CEO Flemming Ornskov.
You may also be interested in...
Shire CEO Says Lanadelumab Results Vindicate Dyax Buy, M&A Strategy
Shire's CEO is savoring a personal victory after Phase III data for lanadelumab in acute HAE replicated impressive Phase Ib trial results that underpinned his 2015 decision to buy Dyax.
Running The Drug Catalyst Gauntlet: What To Look For In Q2 2017
Neurotrope's novel bryostatin treatment for Alzheimer's, AstraZeneca's durvalumab in bladder cancer, and Actelion’s antibiotic cadazolid are among a raft of therapies scheduled for major data read-outs or approval decisions in Q2 2017. With the help of Informa Pharma Intelligence’s Biomedtracker, Scrip takes a look at some crucial drug displays likely over the next three months.
Shire's Wellhoefer On Genetic Disease R&D And Expanding Access To Medicines
Scrip spoke with Shire's Head of Genetic Diseases, Medical Affairs, Hartmann Wellhoefer about upcoming milestones in the company's R&D pipeline and improving access to medicines for rare diseases after the Baxalta merger.